Considering the high potency of ecnoglutide, it might also serve as a viable option for individuals who do not achieve sufficient weight reduction with existing GLP-1 receptor agonists at their approved doses or need to achieve a larger reduction in bodyweight, Ji added
IV therapy frequency is the schedule of intravenous infusion sessions that best supports your specific health goals, ranging from multiple times per week during acute needs to once monthly for general maintenance
Concerns About Stopping GLP-1s 49% of British women and 42% of American women plan to stop GLP-1s once they reach their goal, while 27% in both countries intend to take them indefinitely
However, increasing use of cardioprotective therapies (e.g., statins, SGLT2 inhibitors) and improved risk factor control over time may lower baseline event rates, potentially attenuating the absolute number of preventable events
Adams JM, Pei H, Sandoval DA, et al